Published in J Mol Neurosci on August 13, 2009
New structural scaffolds for centrally acting oxime reactivators of phosphylated cholinesterases. J Biol Chem (2011) 1.14
Novel brain-penetrating oximes for reactivation of cholinesterase inhibited by sarin and VX surrogates. Ann N Y Acad Sci (2016) 0.75
Cost-effectiveness of rosuvastatin compared with other statins from a managed care perspective. Value Health (2005) 1.50
Inhaled corticosteroids plus salmeterol or montelukast: effects on resource utilization and costs. J Allergy Clin Immunol (2002) 1.42
Control of nerve agent-induced seizures is critical for neuroprotection and survival. Toxicol Appl Pharmacol (2003) 1.35
Determinants of compliance with statin therapy and low-density lipoprotein cholesterol goal attainment in a managed care population. Am J Manag Care (2005) 1.22
Co-compartmentalization of the astroglial glutamate transporter, GLT-1, with glycolytic enzymes and mitochondria. J Neurosci (2011) 1.18
Neuronal activity and glutamate uptake decrease mitochondrial mobility in astrocytes and position mitochondria near glutamate transporters. J Neurosci (2014) 0.97
Reactivation of brain acetylcholinesterase by monoisonitrosoacetone increases the therapeutic efficacy against nerve agents in guinea pigs. Chem Biol Interact (2010) 0.94
Anticonvulsants for nerve agent-induced seizures: The influence of the therapeutic dose of atropine. J Pharmacol Exp Ther (2006) 0.90
In vivo reactivation by oximes of inhibited blood, brain and peripheral tissue cholinesterase activity following exposure to nerve agents in guinea pigs. Chem Biol Interact (2010) 0.88
A new derivative of valproic acid amide possesses a broad-spectrum antiseizure profile and unique activity against status epilepticus and organophosphate neuronal damage. Epilepsia (2011) 0.88
Rosuvastatin is cost-effective in treating patients to low-density lipoprotein-cholesterol goals compared with atorvastatin, pravastatin and simvastatin: analysis of the STELLAR trial. Eur J Cardiovasc Prev Rehabil (2005) 0.87
Stereoselective anticonvulsant and pharmacokinetic analysis of valnoctamide, a CNS-active derivative of valproic acid with low teratogenic potential. Epilepsia (2013) 0.86
Gauging the treatment gap in dyslipidemia: findings from the 1999-2000 National Health and Nutrition Examination Survey. Am Heart J (2005) 0.86
Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma. Chest (2002) 0.84
Soman increases neuronal COX-2 levels: possible link between seizures and protracted neuronal damage. Neurotoxicology (2010) 0.84
Protection against sarin-induced seizures in rats by direct brain microinjection of scopolamine, midazolam or MK-801. J Mol Neurosci (2009) 0.83
In vivo cholinesterase inhibitory specificity of organophosphorus nerve agents. Chem Biol Interact (2005) 0.82
Patterns and effectiveness of lipid-lowering therapies in a managed care environment. Value Health (2005) 0.81
Evaluation of nine oximes on in vivo reactivation of blood, brain, and tissue cholinesterase activity inhibited by organophosphorus nerve agents at lethal dose. Toxicol Mech Methods (2009) 0.80
The oxime pro-2-PAM provides minimal protection against the CNS effects of the nerve agents sarin, cyclosarin, and VX in guinea pigs. Toxicol Mech Methods (2010) 0.79
LDL-C reductions and goal attainment among naive statin users in the Netherlands: real life results. Curr Med Res Opin (2008) 0.79
Stereoselective pharmacodynamic and pharmacokinetic analysis of sec-Butylpropylacetamide (SPD), a new CNS-active derivative of valproic acid with unique activity against status epilepticus. J Med Chem (2013) 0.79
Valnoctamide and sec-butyl-propylacetamide (SPD) for acute seizures and status epilepticus. Epilepsia (2013) 0.79
In vivo oxime administration does not influence Ellman acetylcholinesterase assay results. Toxicol Mech Methods (2009) 0.78
In vivo microdialysis and electroencephalographic activity in freely moving guinea pigs exposed to organophosphorus nerve agents sarin and VX: analysis of acetylcholine and glutamate. Arch Toxicol (2011) 0.77
Effects of 4-pyridine aldoxime on nerve agent-inhibited acetylcholinesterase activity in guinea pigs. Arch Toxicol (2009) 0.77
The Toxicity of Soman in the African Green Monkey (Chlorocebus aethiops). Toxicol Mech Methods (2007) 0.77
Enantioselective pharmacodynamic and pharmacokinetic analysis of two chiral CNS-active carbamate derivatives of valproic acid. Epilepsia (2014) 0.77
Comparison of extracellular striatal acetylcholine and brain seizure activity following acute exposure to the nerve agents cyclosarin and tabun in freely moving guinea pigs. Toxicol Mech Methods (2010) 0.76
Neuropharmacological specificity of brain structures involved in soman-induced seizures. Neurotoxicology (2012) 0.76
Kinetics of sarin (GB) following a single sublethal inhalation exposure in the guinea pig. Inhal Toxicol (2007) 0.75
Changes in extracellular striatal acetylcholine and brain seizure activity following acute exposure to nerve agents in freely moving guinea pigs. Toxicol Mech Methods (2010) 0.75
Immunomodulation by poly-YE reduces organophosphate-induced brain damage. Brain Behav Immun (2011) 0.75